The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology

International Journal of Developmental Biology

Volumn 55, Issue 7-9, 2011, Pages 685-696

  Eccles, Suzanne A ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

c Erb B2; c Erb B3; c Erb B4; Cancer; EGFR

Indexed keywords

4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; 5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AC 480; AFATINIB; BEVACIZUMAB; CANERTINIB; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ERTUMAXOMAB; FULVESTRANT; GEFITINIB; GROWTH FACTOR RECEPTOR; LAPATINIB; MM 111; NERATINIB; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; PROTEIN ERB B3; PROTEIN ERB B4; RETASPIMYCIN; TAMOXIFEN; TANESPIMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARLITINIB;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST DEVELOPMENT; CANCER INVASION; CANCER STEM CELL; CELL INTERACTION; DRUG MECHANISM; DRUG TARGETING; EPITHELIUM CELL; GENE MUTATION; HUMAN; LACTATION; LUNG CANCER; METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; LIGANDS; MICE; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEINS V-ERBB; PREGNANCY; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 82555185376     PISSN: 02146282     EISSN: None     Source Type: Journal    
DOI: 10.1387/ijdb.113396se     Document Type: Article

References (56)

1. ALEXI, X., BERDITCHEVSKI, F. and ODINTSOVA, E. (2011). The effect of cell-ECM adhesion on signalling via the ErbB family of growth factor receptors. Biochem Soc Trans 39: 568-573.
2. ARRIBAS, J., BASELGA, J., PEDERSEN, K. and PARRA-PALAU, J.L. (2011). p95HER2 and breast cancer. Cancer Res 71: 1515-1519.
3. BASELGA, J. and SWAIN, S.M. (2010). CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer 10: 489-491.
4. BLOBEL, C.P., CARPENTER, G. and FREEMAN, M. (2009). The role of protease activity in ErbB biology. Exp Cell Res 315: 671-682.
5. BORRIELLO, M., LACCETTI, P., TERRAZZANO, G., D'ALESSIO, G. and DE LORENZO, C. (2011). A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours. Br J Cancer 104: 1716-1723.
6. BOS, P.D., ZHANG, X.H., NADAL, C., SHU, W., GOMIS, R.R., NGUYEN, D.X., MINN, A.J., VAN DE VIJVER, M.J., GERALD, W.L., FOEKENS, J.A. et al., (2009). Genes that mediate breast cancer metastasis to the brain. Nature 459: 1005-1009.
7. BRAUN, S., SCHLIMOK, G., HEUMOS, I., SCHALLER, G., RIETHDORF, L., RIETHMULLER, G. and PANTEL, K. (2001). ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61: 1890-1895.
8. BURGA, L.N., HU, H., JUVEKAR, A., TUNG, N.M., TROYAN, S.L., HOFSTATTER, E.W. and WULF, G.M. (2011). Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice. Breast Cancer Res 13: R30. doi:10.1186/bcr2850.
9. BURNESS, M.L., GRUSHKO, T.A. and OLOPADE, O.I. (2010). Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J 16: 23-32.
10. CAPALA, J. and BOUCHELOUCHE, K. (2010). Molecular imaging of HER2-positive breast cancer: a stef toward an individualized 'image and treat' strategy Curr Opin Oncol 22: 559-566.
11. CITRI, A. and YARDEN, Y. (2006). EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516.
12. COHEN, S. (1997). EGF and its receptor: historical perspective. Introduction. J Mammary Gland Biol Neoplasia 2: 93-96.
13. COLOMBO, M., CORSI, F., FOSCHI, D., MAZZANTINI, E., MAZZUCCHELLI, S., MORASSO, C., OCCHIPINTI, E., POLITO, L., PROSPERI, D., RONCHI, S. et al., (2010). HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches. Pharmacol Res 62: 150-165.
14. DAWSON, S.J., PROVENZANO, E. and CALDAS, C. (2009). Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 45 Suppl 1: 27-40.
15. DE LUCA, A., GALLO, M., ALDINUCCI, D., RIBATTI, D., LAMURA, L., D'ALESSIO, A., DE FILIPPI, R., PINTO, A. and NORMANNO, N. (2011). Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. J Cell Physiol 226: 2131-2138.
16. DENARDO, D.G., CUBA, V.L., KIM, H., WU, K., LEE, A.V. and BROWN, P.H. (2007). Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth. Mol Cell Endocrinol 277: 13-25.
17. ECCLES, S.A. (2001). The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 6: 393-406.
18. ECCLES, S.A., MASSEY, A., RAYNAUD, F.I., SHARP, S.Y., BOX, G., VALENTI, M., PATTERSON, L., DE HAVEN BRANDON, A., GOWAN, S., BOXALL, F. et al., (2008). NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68: 2850-2860.
19. ECCLES, S.A. and PAON, L. (2005). Breast cancer metastasis: when, where, how? Lancet 365: 1006-1007.
20. ECCLES, S.A. and WELCH, D.R. (2007). Metastasis: recent discoveries and novel treatment strategies. Lancet 369: 1742-1757.
21. FOLEY, J., NICKERSON, N.K., NAM, S., ALLEN, K.T., GILMORE, J.L., NEPHEW, K.P. and RIESE, D.J., 2ND. (2010). EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol 21: 951-960.
22. GARRETT, J.T. and ARTEAGA, C.L. (2011). Resistance to HER2-directed antibody ies and tyrosine kinase inhibitors: Mechanisms and clinical implications. Cancer Biol Ther 11.
23. GATZA, M.L., KUNG, H.N., BLACKWELL, K.L., DEWHIRST, M.W., MARKS, J.R. and CHI, J.T. (2011). Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2 related breast tumor subtypes. Breast Cancer Res 13: R62. doi:10.1186/bcr2899.
24. GIJSEN, M., KING, P., PERERA, T., PARKER, P.J., HARRIS, A.L., LARIJANI, B. and KONG, A. (2010). HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol 8: e1000563.
25. GOEL, S., CHIRGWIN, J., FRANCIS, P., STUART-HARRIS, R., DEWAR, J., MILESHKIN, L., SNYDER, R., MICHAEL, M. and KOCZWARA, B. (2011). Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications of recent research. Breast 20: 101-110.
26. GRASSIAN, A.R., SCHAFER, Z.T. and BRUGGE, J.S. (2011). ErbB2 stabilizes epidermal growth factor receptor (EGFR) expression via Erk and Sprouty2 in extracellular matrix-detached cells. J Biol Chem 286: 79-90.
27. GUISE, T. (2010). Examining the metastatic niche: targeting the microenvironment. Semin Oncol 37 Suppl 2: S2-S14.
28. HIGASHIYAMA, S., IWABUKI, H., MORIMOTO, C., HIEDA, M., INOUE, H. and MATSUSHITA, N. (2008). Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci 99: 214-220.
29. HUTCHESON, I.R., GODDARD, L., BARROW, D., MCCLELLAND, R.A., FRANCIES, H.E., KNOWLDEN, J.M., NICHOLSON, R.I. and GEE, J.M. (2011). Fulvestrantinduced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptorpositive breast cancer cells to heregulin beta1. Breast Cancer Res 13: R29. doi:10.1186/bcr2848.
30. JIN, Q. and ESTEVA, F.J. (2008). Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13: 485-498.
31. JONES, F.E. (2008). HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J Mammary Gland Biol Neoplasia 13: 247-258.
32. KANG, Y., SIEGEL, P.M., SHU, W., DROBNJAK, M., KAKONEN, S.M., CORDONCARDO, C., GUISE, T.A. and MASSAGUE, J. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549.
33. KENNY, P.A. and BISSELL, M.J. (2007). Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 117: 337-345.
34. LADJEMI, M.Z., JACOT, W., CHARDES, T., PELEGRIN, A. and NAVARRO-TEULON, I. (2010). Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 59: 1295-1312.
35. MA, L., HUET, E., SEROVA, M., BERTHOIS, Y., CALVO, F., MOURAH, S. and MENASHI, S. (2010). Antisense inhibition of amphiregulin expression reduces EGFR phosphorylation in transformed human breast epithelial cells. Anticancer Res 30: 2101-2016.
36. MCINTYRE, E., BLACKBURN, E., BROWN, P.J., JOHNSON, C.G. and GULLICK, W.J. (2010). The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer. Breast Cancer Res Treat 122: 105-110.
37. MENG, L., HUNT, C., YAGLOM, J.A., GABAI, V.L. and SHERMAN, M.Y. (2011). Heat shock protein Hsp72 plays an essential role in Her2-induced mammary tumorigenesis. Oncogene 30: 2836-2845.
38. MODI, S., STOPECK, A., LINDEN, H., SOLIT, D., CHANDARLAPATY, S., ROSEN, N., D'ANDREA, G., DICKLER, M., MOYNAHAN, M.E., SUGARMAN, S. et al., (2011). HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. Clin Cancer Res 17: 5132-5139.
39. O'BRIEN, C.S., FARNIE, G., HOWELL, S.J. and CLARKE, R.B. (2011). Breast cancer stem cells and their role in resistance to endocrine therapy. Horm Cancer 2: 91-103.
40. PALMIERI, D., BRONDER, J.L., HERRING, J.M., YONEDA, T., WEIL, R.J., STARK, A.M., KUREK, R., VEGA-VALLE, E., FEIGENBAUM, L., HALVERSON, D. et al., (2007). Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 67: 4190-4198.
41. PRENZEL, N., ZWICK, E., LESERER, M. and ULLRICH, A. (2000). Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal intregratioan and diversification. Breast Cancer Res 2: 184-190.
42. PROCTER, M., SUTER, T.M., DE AZAMBUJA, E., DAFNI, U., VAN DOOREN, V., MUEHLBAUER, S., CLIMENT, M.A., RECHBERGER, E., LIU, W.T., TOI, M. et al., (2010). Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 28: 3422-3428.
43. SAHIN, U., WESKAMP, G., KELLY, K., ZHOU, H.M., HIGASHIYAMA, S., PESCHON, J., HARTMANN, D., SAFTIG, P. and BLOBEL, C.P. (2004). Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164: 769-779.
44. SCHMIDT, C. (2008). Lapatinib study supports cancer stem cell hypothesis, encourages industry research. J Natl Cancer Inst 100: 694-695.
45. SCHULZE, W.X., DENG, L. and MANN, M. (2005). Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1: 2005 0008.
46. SEOANE, S., MONTERO, J.C., OCANA, A. and PANDIELLA, A. (2010). Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. J Natl Cancer Inst 102: 1432-1446.
47. SHI, F., TELESCO, S.E., LIU, Y., RADHAKRISHNAN, R. and LEMMON, M.A. (2010). ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A 107: 7692-7697.
48. SMIRNOVA, T., ZHOU, Z.N., FLINN, R.J., WYCKOFF, J., BOIMEL, P.J., POZZUTO, M., CONIGLIO, S.J., BACKER, J.M., BRESNICK, A.R., CONDEELIS, J.S. et al., (2011). Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene. doi:10.1038/onc.2011.275.
49. SORLIE, T. (2004). Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 40: 2667-2675.
50. STERN, D.F. (2008). ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 13: 215-223.
51. STERNLICHT, M.D. and SUNNARBORG, S.W. (2008). The ADAM17-amphiregulin-EGFR axis in mammary development and cancer. J Mammary Gland Biol Neoplasia 13: 181-194.
52. SUNDVALL, M., ILJIN, K., KILPINEN, S., SARA, H., KALLIONIEMI, O.P. and ELENIUS, K. (2008). Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia 13: 259-268.
53. SUTHERLAND, R.L. (2011). Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4. Breast Cancer Res 13: 106. doi:10.1186/bcr2878.
54. SUTTON, L.M., HAN, J.S., MOLBERG, K.H., SARODE, V.R., CAO, D., RAKHEJA, D., SAILORS, J. and PENG, Y. (2010). Intratumoral expression level of epidermal groth factor respector and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma. Am J Clin Pathol 134: 782-787.
55. VAN LAERE, S.J., VAN DER AUWERA, I., VAN DEN EYNDEN, G.G., VAN DAM, P., VAN MARCK, E.A., VERMEULEN, P.B. and DIRIX, L.Y. (2007). NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. Br J Cancer 97: 659-669.
56. ZHANG, S., HUANG, W.C., LI, P., GUO, H., POH, S.B., BRADY, S.W., XIONG, Y., TSENG, L.M., LI, S.H., DING, Z. et al., (2011). Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17: 461-469.